Regeneron (REGN) Tops Q4 EPS by $1.06, Revenues Beat; Offers FY19 Financial Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Regeneron Pharma (REGN) PT Raised to $480 at Oppenheimer
February 7, 2019 8:15 AM ESTOppenheimer analyst Hartaj Singh raised the price target on Regeneron Pharma (NASDAQ: REGN) to $480.00 (from $440.00) while maintaining a Outperform rating.
Singh commented, "REGN reported 4Q18 sales/earnings and provided a business update on 02/06. The company's Eylea US (and ex-US) sales were 5-9% above OPCO... More
Regeneron Pharma (REGN) PT Raised to $410 at BMO Capital
February 6, 2019 3:25 PM ESTBMO Capital analyst Brian Skorney raised the price target on Regeneron Pharma (NASDAQ: REGN) to $410.00 (from $388.00) while maintaining a Market Perform rating, saying they are incrementally positive on earnings.
Skorney commented, "Regeneron reported strong fourth quarter earnings coming in ahead of both top- and... More
UPDATE: Sanofi (SNY), Regeneron (REGN) Report CHMP Recommends Approval of Praluent (alirocumab) to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease
February 4, 2019 5:56 AM EST(Updated - February 4, 2019 5:57 AM EST)
Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN) announce the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Praluent® (alirocumab), recommending a new indication as an adjunct to correction of other risk factors. Praluent should be used in addition to a maximally tolerated dose of statin or can be used alone in patients intolerant to or inappropriate for statin therapy.
ASCVD is an umbrella term,... More
